Citations

Clear

1031 citation(s) found for "Clark, AS".

Serum Reference Intervals and Diagnostic Ranges for Free κ and Free λ Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains
Katzmann, Jerry A., Clark, Raynell, Abraham, Roshini S. , Bryant, Sandra C. , Lymp, James, Kyle, Robert A. , Bradwell, A.R.

Mayo Clinic

Clinical Chemistry | January 24, 2020 | Volume: 48 | Issue: 9 | Pages: 1437-1444

10.1093/clinchem/48.9.1437 Get It

AbstractBackground: The detection of monoclonal free light chains (FLCs) is an important diagnostic aid for a variety of monoclonal gammopathies and is especially important in light-chain diseases, such as light-chain myeloma, primary systemic amyloidosis, and light-chain-deposition disease. These diseases are more prevalent in the elderly, and assays to detect and quantify abnormal amounts of FLCs require reference intervals that include elderly donors.Methods: We used an automated immunoassay for FLCs and sera from a population 21–90 years of age. We used the calculated reference and diagnostic intervals to compare FLC results with those obtained by immunofixation (IFE) to detect low concentrations of monoclonal κ and λ FLCs in the sera of patients with monoclonal gammopathies.Results: Serum κ and λ FLCs increased with population age, with an apparent change for those >80 years. This trend was lost when the FLC concentration was normalized to cystatin C concentration. The ratio of κ FLC to λ FLC (FLC K/L) did not exhibit an age-dependent trend. The diagnostic interval for FLC K/L was 0.26–1.65. The 95% reference interval for κ FLC was 3.3–19.4 mg/L, and that for λ FLC was 5.7–26.3 mg/L. Detection and quantification of monoclonal FLCs by nephelometry were more sensitive than IFE in serum samples from patients with primary systemic amyloidosis and light-chain-deposition disease.Conclusions: Reference and diagnostic intervals for serum FLCs have been developed for use with a new, automated immunoassay that makes the detection and quantification of monoclonal FLCs easier and more sensitive than with current methods. The serum FLC assay complements IFE and allows quantification of FLCs in light-chain-disease patients who have no detectable serum or urine M-spike.
Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium
Miyagawa, Toji , Brushaber, Danielle , Syrjanen, Jeremy A. , Kremers, Walter K. , Fields, Julie A. , Forsberg, Leah K. , Heuer, Hilary W. , Kornak, John , Boxer, Adam L. , Rosen, Howard J. , Bordelon, Yvette , Bove, Jessica, Brannelly, Patrick , Caso, Christina, Coppola, Giovanni , Dever, Reilly, Dheel, Christina, Dickinson, Susan, Domínguez, S. Carbajal, Domoto‐Reilly, Kimiko , Faber, Kelley , Ferrell, Jessica, Fishman, Ann, Gavrilova, Ralitza H. , Gearhart, Debra, Ghazanfari, Behnaz, Ghoshal, Nupur , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Grant, Ian , Haley, Dana , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Jones, Lynne C. , Kantarci, Kejal , Karydas, Anna, Kaufer, Daniel , Kraft, Ruth, Kramer, Joel H. , Kukull, Walter A. , Lucente, Diane , Lungu, Codrin , Mackenzie, Ian R. , Maldonado, Miranda, Manoochehri, Masood , McGinnis, Scott, McKinley, Emily , Mendez, Mario F. , Miller, Bruce L. , Multani, Namita, Onyike, Chiadi U. , Padmanabhan, Jaya , Pantelyat, Alexander , Pearlman, Rodney , Petrucelli, Leonard , Potter, Madeline, Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Kate, Rascovsky, Katya, Roberson, Erik D. , Rogalskı, Emily , Sengdy, Pheth, Shaw, Leslie M. , Tartaglia, Maria Carmela , Tatton, Nadine , Taylor, Joanne, Toga, Arthur W. , Trojanowski, John Q. , Wang, Ping , Weıntraub, Sandra , Wong, Bonnie , Irwin, David J , Hsiung, Gink-Yuek , Roberson, Erik , Miller, Bruce L , Kantarci, Kejal , Pantelyat, Alex , Tartaglia, Maria Carmela , Kremers, Walter K , Domoto-Reilly, Kimiko , Knopman, David S. , Boeve, Bradley F. , Appleby, Brian S. , Dickerson, Bradford Clark , Fong, Jamie , Foroud, Tatiana , Goldman, Jill , Grossman, Murray , Jones, David T. , Jones, Lynne, Kerwin, Diana , Litvan, Irene , Wszołek, Zbigniew K.

Mayo Clinic

Alzheimer's & Dementia | January 16, 2020 | Volume: 16 | Issue: 1 | Pages: 106-117

10.1002/alz.12033 | PMID 31914218 Get It

AbstractIntroductionWe created global rating scoring rules for the CDR® plus NACC FTLD to detect and track early frontotemporal lobar degeneration (FTLD) and to conduct clinical trials in FTLD.MethodsThe CDR plus NACC FTLD rating was applied to 970 sporadic and familial participants from the baseline visit of Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL)/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS). Each of the eight domains of the CDR plus NACC FTLD was equally weighed in determining the global score. An interrater reliability study was completed for 40 participants.ResultsThe CDR plus NACC FTLD showed very good interrater reliability. It was especially useful in detecting clinical features of mild non‐fluent/agrammatic variant primary progressive aphasia participants.DiscussionThe global CDR plus NACC FTLD score could be an attractive outcome measure for clinical trials in symptomatic FTLD, and may be useful in natural history studies and clinical trials in FTLD spectrum disorders.
Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases
Ramos, Eliana Marisa , Dokuru, Deepika , Berlo, Victoria Van, Wojta, Kevin , Huang, Alden , Deverasetty, Sandeep, Qin, Yue , Blitterswijk, Marka van , Jackson, Jazmyne L. , Bordelon, Yvette , Brannelly, Patrick , Brushaber, Danielle , Dickinson, Susan, Domoto‐Reilly, Kimiko , Faber, Kelley , Fields, Julie A. , Forsberg, Leah K. , Gavrilova, Ralitza H. , Ghoshal, Nupur , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Grant, Ian , Heuer, Hilary W. , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Karydas, Anna, Kaufer, Daniel , Kornak, John , Kramer, Joel H. , Kremers, Walter K. , Kukull, Walter A. , Ljubenkov, Peter A. , Lungu, Codrin , Mackenzie, Ian R. , Mendez, Mario F. , Miller, Bruce L. , Onyike, Chiadi U. , Pantelyat, Alexander , Pearlman, Rodney , Petrucelli, Len, Potter, Madeline, Rankin, Katherine P. , Rascovsky, Katya, Roberson, Erik D. , Rogalskı, Emily , Shaw, Leslie M. , Syrjanen, Jeremy A. , Tartaglia, Maria Carmela , Tatton, Nadine , Taylor, Joanne, Trojanowski, John Q. , Weıntraub, Sandra , Wong, Bonnie , Rademakers, Rosa , Rosen, Howard J. , Boxer, Adam L. , Coppola, Giovanni, Jackson, Jazmyne, Brushaber, Danielle E, Boeve, Brad F, van Blitterswijk, Marka , Irwin, David J , Hsiung, Gink-Yuek , Roberson, Erik , Miller, Bruce L , Kantarci, Kejal , Pantelyat, Alex , Tartaglia, Maria Carmela , Kremers, Walter K , Domoto-Reilly, Kimiko , Wang, Qing , Appleby, Brian S. , Dickerson, Bradford Clark , Fong, Jamie , Foroud, Tatiana , Goldman, Jill , Grossman, Murray , Kerwin, Diana , Knopman, David S. , Litvan, Irene , Toga, Arthur W. , Wszołek, Zbigniew K. , Boeve, Bradley F. , Coppola, Giovanni

Mayo Clinic

Alzheimer's & Dementia | January 16, 2020 | Volume: 16 | Issue: 1 | Pages: 118-130

10.1002/alz.12011 | PMID 31914217 Get It

AbstractIntroductionThe Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) consortia are two closely connected studies, involving multiple North American centers that evaluate both sporadic and familial frontotemporal dementia (FTD) participants and study longitudinal changes.MethodsWe screened the major dementia‐associated genes in 302 sporadic and 390 familial (symptomatic or at‐risk) participants enrolled in these studies.ResultsAmong the sporadic patients, 16 (5.3%) carried chromosome 9 open reading frame 72 (C9orf72), microtubule‐associated protein tau (MAPT), and progranulin (GRN) pathogenic variants, whereas in the familial series we identified 207 carriers from 146 families. Of interest, one patient was found to carry a homozygous C9orf72 expansion, while another carried both a C9orf72 expansion and a GRN pathogenic variant. We also identified likely pathogenic variants in the TAR DNA binding protein (TARDBP), presenilin 1 (PSEN1), and valosin containing protein (VCP) genes, and a subset of variants of unknown significance in other rare FTD genes.DiscussionOur study reports the genetic characterization of a large FTD series and supports an unbiased sequencing screen, irrespective of clinical presentation or family history.
Dementia palliative care in the acute psychiatric hospital: A feasibility study
Gentry, Melanie T. , Clark, Matthew M. , Rummans, Teresa A. , Ryan, Susan M, Gentry, Melanie T , Ryan, Susan , Lapid, Maria I.

Mayo Clinic

Perspectives in Psychiatric Care | January 15, 2020 | Volume: 56 | Issue: 3 | Pages: 593-597

10.1111/ppc.12473 | PMID 31944318 Get It

AbstractPurposeWe explored the feasibility of a clinical pathway to identify hospitalized patients with dementia who would benefit from a palliative intervention.Design and MethodsConsecutive geropsychiatric admissions were screened for terminal dementia to be randomized to a palliative consultation vs usual care.FindingsA total of 43 of the 188 patients (23%) had dementia; however, dementia stages were severe but not terminal. The pathway was not feasible because of the lack of the target population in the inpatient setting for the intervention.Practice ImplicationsNew clinical pathways are needed to identify patients with dementia who would benefit from palliative care.
Evaluation of commercially available acridinium ester-labeled chemiluminescent DNA probes for culture identification of Blastomyces dermatitidis, Coccidioides immitis, Cryptococcus neoformans, and Histoplasma capsulatum
Stockman, L, Clark, Kristen , Hunt, John, Roberts, Glenn D., Hunt, J M

Mayo Clinic

Journal of Clinical Microbiology | January 5, 2020 | Volume: 31 | Issue: 4 | Pages: 845-850

10.1128/jcm.31.4.845-850.1993 | PMID 8463395 Get It

Four commercially available acridinium ester-labeled DNA probes directed against rRNA were evaluated for their ability to identify Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, and Cryptococcus neoformans in culture. rRNA was extracted by sonication of 1- to 2-mm2 portions of cultures of fungi in two chaotropic reagents with glass beads. Following a heat inactivation step, the extracts were hybridized in solution with probes specific for each pathogen. The acridinium ester reporter moiety of nonhybridized probe was selectively hydrolyzed, and chemiluminescence of specific DNA:RNA hybrids was quantitated in relative light units with a luminometer. A positive identification required a relative light unit value of > or = 50,000. Sensitivity and specificity of the probes were determined by probing cultures of the respective pathogenic fungi (target) and nontarget fungi. Both mycelial and yeast forms of the dimorphic fungi (B. dermatitidis and H. capsulatum) were tested. For B. dermatitidis, sensitivity and specificity were 87.8 and 100%, respectively (74 target and 219 nontarget fungi tested). For C. immitis, sensitivity and specificity were 99.2 and 100%, respectively (122 target and 164 nontarget fungi tested). For H. capsulatum, sensitivity and specificity were 100 and 100%, respectively (86 target and 154 nontarget fungi tested). For C. neoformans, sensitivity and specificity were 97 and 100%, respectively (100 target and 230 nontarget fungi tested). For B. dermatitidis, C. immitis, and C. neoformans, repeat testing increased the respective sensitivities to 97.3, 100, and 100%. The high sensitivities and specificities of the probes, the relatively short time (less than 1 h) required to perform the assay, and the availability of standardized reagent kits make the acridinium ester-labeled DNA probes well suited to laboratories in need of a rapid method to identify these fungal pathogens. Further, use of the probes to identify pathogenic fungi as soon as colonies appear on primary recovery media significantly shortens the time to reporting.
Allopathic (MD) and Osteopathic (DO) Performance on the American Board of Physical Medicine and Rehabilitation Initial Certifying Examinations
Sliwa, James A. , Raddatz, Mikaela M. , Kinney, Carolyn L. , Clark, Gary S., Kinney, Carolyn , Robinson, Lawrence R.

Mayo Clinic

PM&R | December 28, 2019 | Volume: 12 | Issue: 9 | Pages: 899-903

10.1002/pmrj.12311 | PMID 31883237 Get It

BackgroundOsteopathic physicians (DOs) represent over 30% of residents in allopathic (MD) Accreditation Council for Graduate Medical Education (ACGME) accredited physical medicine and rehabilitation (PM&R) training programs. However, some have questioned the quality of osteopathic medical school training and the graduates of osteopathic medical schools. The performance of osteopathic physicians in allopathic PM&R training programs has not been assessed.ObjectiveTo compare allopathic (MD) and osteopathic (DO) physician performance on American Board of Physical Medicine and Rehabilitation (ABPMR) initial certifying examinations.DesignRetrospective cross‐sectional study.SettingBoard‐eligible PM&R physicians.ParticipantsMDs and DOs who completed an allopathic ACGME‐accredited PM&R residency training program.MethodsMD and DO pass rates and mean scaled scores on the ABPMR initial certifying examinations were compared. MD versus DO degrees and training program 6 years aggregate board pass rates were independent variables.InterventionsNot applicable.Main Outcome MeasureMD and DO pass rates and mean scaled scores on the ABPMR initial certifying examinations.ResultsOf the 2187 physicians who were first‐time ABPMR initial certifying examination takers, there were 1596 MDs (73%) and 591 DOs (27%). No statistically significant difference was found in pass rates between MDs and DOs on Part I (94.9% vs. 93.9%, P = .35) or Part II (87.8% vs. 88%, P = .83) of the ABPMR certifying examination. Analysis of mean scaled scores demonstrated higher MD scores on both Part I ( 526, SD = 31, vs. 516, SD = 67, P = .002) and Part II ( 6.73, SD = .83 vs. 6.62, SD = .77, P = .005), significant only in programs with a 90%‐100% pass rate. These differences, however, were of very small magnitude and likely not meaningful from a clinical or educational perspective.ConclusionThis study did not find meaningful differences in performance on the ABPMR certifying examinations between MDs and DOs.
Expanding the CRISPR Toolbox with ErCas12a in Zebrafish and Human Cells
Wierson, Wesley A. , Simone, Brandon W. , WareJoncas, Zachary , Mann, Carla M. , Welker, Jordan M. , Kar, Bibekananda , Emch, Michael J. , Gendron, William A.C. , Kar, Bibekananda , Friedberg, Iddo , Barry, Michael A. , Clark, Karl J. , Dobbs, Drena L , McGrail, Maura , Ekker, Stephen C. , Essner, Jeffrey J.

Mayo Clinic

The CRISPR Journal | December 20, 2019 | Volume: 2 | Issue: 6 | Pages: 417-433

10.1089/crispr.2019.0026 | PMID 31742435 Get It

CRISPR and CRISPR-Cas effector proteins enable the targeting of DNA double-strand breaks to defined loci based on a variable length RNA guide specific to each effector. The guide RNAs are generally similar in size and form, consisting of a ∼20 nucleotide sequence complementary to the DNA target and an RNA secondary structure recognized by the effector. However, the effector proteins vary in protospacer adjacent motif requirements, nuclease activities, and DNA binding kinetics. Recently, ErCas12a, a new member of the Cas12a family, was identified in Eubacterium rectale . Here, we report the first characterization of ErCas12a activity in zebrafish and expand on previously reported activity in human cells. Using a fluorescent reporter system, we show that CRISPR-ErCas12a elicits strand annealing mediated DNA repair more efficiently than CRISPR-Cas9. Further, using our previously reported gene targeting method that utilizes short homology, GeneWeld, we demonstrate the use of CRISPR-ErCas12a to integrate reporter alleles into the genomes of both zebrafish and human cells. Together, this work provides methods for deploying an additional CRISPR-Cas system, thus increasing the flexibility researchers have in applying genome engineering technologies.
Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients
Whitmire, Paula , Rickertsen, Cassandra , Lorence, Julia, León, Gustavo De , Bayless, Spencer, Clark-Swanson, Kamala , Corpuz, Christina, Angeles, Christine Paula Lewis-de los, Vora, Sujay A., Mrugała, Maciej M. , Hu, Leland , Porter, Alyx B. , Kumthekar, Priya , Johnston, Sandra K. , Egan, Kathleen M. , Canoll, Peter , Swanson, Kristin R. , Swanson, Kristin R , Hawkins‐Daarud, Andrea , Carrasco, Eduardo, Leon, Gustavo De, Curtin, Lee , Peeri, Noah Charles , Bendok, Bernard R. , Gonzalez‐Cuyar, Luis F. , Wang, Lei G. , Gatenby, Robert A. , Rubin, Joshua B

Mayo Clinic

No container title available | December 19, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.10177/v3 Get It

Abstract Background : Sex is recognized as a significant determinant of outcome among glioblastoma patients, but the relative prognostic importance of glioblastoma features has not been thoroughly explored for sex differences. Methods : Combining multi-modal MR images, biomathematical models, and patient clinical information, this investigation assesses which pretreatment variables have a sex-specific impact on the survival of glioblastoma patients (299 males and 195 females). Results : Among males, tumor (T1Gd) radius was a predictor of overall survival (HR=1.027, p=0.044). Among females, higher tumor cell net invasion rate was a significant detriment to overall survival (HR=1.011, p<0.001). Female extreme survivors had significantly smaller tumors (T1Gd) (p=0.010 t-test), but tumor size was not correlated with female overall survival (p=0.955 CPH). Both male and female extreme survivors had significantly lower tumor cell net proliferation rates than other patients (M p=0.004, F p=0.001, t-test). Conclusion : Despite similar distributions of the MR imaging parameters between males and females, there was a sex-specific difference in how these parameters related to outcomes.
1496: MULTICENTER STUDY OF ANGIOTENSIN II INFUSION FOR REFRACTORY VASODILATORY SHOCK
Davison, Danielle , Cooper, Craig, Butler, Simona, Clark, Angela, Tendler, Rachel, Wittwer, Erica D. , Frazee, Erin N. , Wieruszewski, Patrick M. , Cooper, Craig, Kashani, Kianoush

Mayo Clinic

Critical Care Medicine | December 18, 2019 | Volume: 48 | Issue: 1 | Pages: 724-724

10.1097/01.ccm.0000647892.97186.bb Get It

Intravascular Large B-cell Lymphoma Associated with Systemic and Central Nervous System Hemophagocytic Lymphohistiocytosis: A Case Report
Verma, Aradhana, Sharma, Akanksha , Robetorye, Ryan S. , Porter, Alyx B. , Robetorye, Ryan, Porter, Alyx, Hilal, Talal

Mayo Clinic

The Permanente Journal | December 6, 2019 | Volume: 24 | Issue: 1 | Pages: No page available

10.7812/tpp/19.105 | PMID 31852057 Get It